 Home > Chemicals Industry > China Chemical > The sales scale of the pharmaceutical industry will reach 1.43 trillion U.S. dollars in 2026

The sales scale of the pharmaceutical industry will reach 1.43 trillion U.S. dollars in 2026

 Last Update: 2022-01-06
 Source: Internet
 Author: User

Tags

2 3 butanediol

1 4 3 4

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

【Chemical machinery and equipment network market analysis ] With the pressure of price reduction and the transition to prevention, diagnosis and practical security, the pharmaceutical industry is undergoing a pain and transformation.
According to data from EvaluatePharma, sales of 872 billion U.
S.
dollars were achieved in 2019, and sales will reach 1.
43 trillion yuan in 2026.

Market analysis of chemical machinery equipment networkChemical machinery and equipment

The development status of the pharmaceutical industry, sales scale fluctuates and rises

With the pressure of lowering prices and the transition to prevention, diagnosis and practical security, the pharmaceutical industry is undergoing a pain and transformation.
In July 2020, EvaluatePharma released the "WorldPreview2020, Outlookto2026" report, pointing out that the sales of prescription drugs from 2010 to 2019 showed a volatile growth trend and achieved sales of 872 billion U.
S.
dollars in 2019.

——Oncology is still the focus of future development

　　From the perspective of the therapeutic field, oncology is still the key development area of today and in the future.
In 2019, its sales reached 145.
4 billion U.
S.
dollars, after which it will soar to 311.
2 billion U.
S.
dollars at a compound annual growth rate of 11.
5%.
* The second is the diabetes field.
Sales in 2019 reached 51 billion U.
S.
dollars, and thereafter, it will reach 66.
9 billion U.
S.
dollars for grandma in 2026 at a compound annual growth rate of 3.
9%.
Furthermore, in terms of immunosuppression, although its sales in 2019 only reached 24 billion U.
S.
dollars, it will increase at a high speed with a compound annual growth rate of 14.
3% to 61.
3 billion U.
S.
dollars in 2026.

　　From the perspective of market share, the market share of oncology treatment in 2019 reached 16%, and it will rise to 21.
7% in 2026, an increase of 5.
8 percentage points from 2019.
The second is the diabetes field, which has a market share of 5.
6% in 2019 and will drop to 4.
7% in 2026, a decrease of 0.
9 percentage points from 2019.
*The third one is immunosuppression.
Its market share reached 2.
6% in 2019, and then climbed to 4.
3% in 2026, an increase of 1.
6 percentage points from 2019.

　　——Roche Group's sales despite shrinking market share*

　　In terms of sales of pharmaceutical companies, Roche Group achieved sales of 48.
2 billion U.
S.
dollars in 2019, and will maintain a 3.
4% growth rate during 2019-2026 to increase to 61 billion U.
S.
dollars.
Second is Johnson & Johnson.
Although it only achieved sales of US$40.
1 billion in 2019, it will achieve sales of about US$56.
1 billion in 2026 with a compound annual growth rate of 4.
9%.
Furthermore, Novartis has sales of 46.
1 billion U.
S.
dollars in 2019, and sales of 54.
8 billion U.
S.
dollars in 2026.

　　From the perspective of the market share of pharmaceutical companies, the concentration of pharmaceutical companies will show a downward trend in 2026.
In 2019, the market share of *0 pharmaceutical companies reached 42%, but it shrank to 35.
7% in 2026, a drop of 6.
2 percentage points.
As far as individual companies are concerned, Roche Group’s market share has always been higher than that of other pharmaceutical companies, achieving a market share of 5.
5% in 2019; with the shrinking concentration of pharmaceutical companies, the Roche Group’s market will shrink to 4.
4 in 2026.
%, a decrease of 1.
1 percentage points from 2019.

　　——Roche Group’s R&D expenditures are in scope

　　From the perspective of R&D, the amount invested by *0 pharmaceutical companies in research and development will show an upward trend year by year.
In 2019, *0 pharmaceutical companies spent a total of US$71.
6 billion on research and development; in 2026, this figure will grow at a compound annual growth rate.
3.
8% rose to about 92.
8 billion US dollars.
Specifically, the Roche Group spent a total of US$10.
3 billion in research and development expenses in 2019, and it will increase to US$12.
9 billion in 2026 at a compound annual growth rate of 3.
3%.
* Second, Merck is not to be outdone, spending 8.
7 billion US dollars as research and development expenses in 2019, and this figure will rise to about 11 billion US dollars in 2026.

　　Although the amount invested by pharmaceutical companies in R&D will show an upward trend year by year, the proportion of investment has shown a downward trend.
Among the *0 pharmaceutical companies, the most serious decline was AstraZeneca; its share in 2019 was 22.
9%, but it will shrink to 18.
3% in 2026, a drop of 4.
6%.
Although the proportion of Roche Group has also shown a shrinking trend, it only fell by 0.
1%, and the proportion of investment in 2026 is almost the same as in 2019.

　　The outlook of the pharmaceutical industry predicts that the sales scale of the pharmaceutical industry will reach US$1.
43 trillion in 2026

　　On the whole, although the concentration of pharmaceutical companies*0 has been declining year by year, competition is still fierce, especially the expenditure on research and development, which has been maintained at a ratio of about 20%.
Looking forward to 2026, according to EvaluatePharma's data, the sales scale of the pharmaceutical industry will reach trillions of oceans in 2021, and it will maintain a trend of constant development; the sales scale of the pharmaceutical industry will reach approximately US$1.
43 trillion in 2026.

　　For more data, please refer to the "China Pharmaceutical R&D Outsourcing (CRO) Industry Market Outlook and Investment Strategic Planning Analysis Report" by the Qianzhan Industry Research Institute.
At the same time, the Qianzhan Industry Research Institute also provides industrial big data, industrial planning, industrial declaration, industrial park planning, and industry Solutions such as investment promotion.

　　Original title: The market status and development prospects of the pharmaceutical industry in 2020 are predicted to reach 1.
43 trillion US dollars in 2026 sales

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.